Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Total Liabilities (2021 - 2025)

Prime Medicine filings provide 5 years of Total Liabilities readings, the most recent being $221.9 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 53.69% to $221.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $221.9 million, a 53.69% increase, with the full-year FY2025 number at $221.9 million, up 53.69% from a year prior.
  • Total Liabilities hit $221.9 million in Q4 2025 for Prime Medicine, down from $223.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $223.2 million in Q3 2025 to a low of $38.1 million in Q1 2023.
  • Median Total Liabilities over the past 5 years was $81.0 million (2021), compared with a mean of $116.3 million.
  • Biggest five-year swings in Total Liabilities: tumbled 79.1% in 2023 and later skyrocketed 245.63% in 2025.
  • Prime Medicine's Total Liabilities stood at $62.3 million in 2021, then decreased by 29.3% to $44.0 million in 2022, then soared by 38.0% to $60.8 million in 2023, then soared by 137.51% to $144.4 million in 2024, then soared by 53.69% to $221.9 million in 2025.
  • The last three reported values for Total Liabilities were $221.9 million (Q4 2025), $223.2 million (Q3 2025), and $218.1 million (Q2 2025) per Business Quant data.